SCHEMBL2525378

SCHEMBL2525378

C#Cc1nccnc1Br.c1cc2cc-2c1

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BIRC5 O15392 1/20 0.30
CLK4 Q9HAZ1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477049 0.80 CYP2A6 (0.33) CLK4
SCHEMBL14976487 0.78 MAP4K4 (0.31) CLK4
SCHEMBL8340916 0.78 MAP4K4 (0.40)
SCHEMBL2522839 0.76 TRIM24 (0.35) CLK4
SCHEMBL1477713 0.74 RORB (0.37) CLK4
SCHEMBL1476448 0.73 NFE2L2 (0.33) CLK4
SCHEMBL1477323 0.73 HDAC8 (0.40) CLK4
SCHEMBL1477483 0.73 CYP2A6 (0.40)
SCHEMBL1476408 0.73 MEN1 (0.35) CLK4
Hydrochloric Acid SCHEMBL1477173 0.71 CYP2A6 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9315498-B2 Arlethynyl derivatives HOFFMAN-LA ROCHE INC. (US) 2016-04-19 US disclosed
EP-2558457-B1 ARYLETHYNYL DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-03-09 EP disclosed
US-20140155602-A1 Arlethynyl Derivatives HOFFMANN-LA ROCHE INC. (US) 2014-06-05 US disclosed
US-8618296-B2 Arylethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2013-12-31 US disclosed
US-20130274464-A1 Arylethynyl Derivatives F. HOFFMANN-LA ROCHE AG (CH) 2013-10-17 US disclosed
US-8513273-B2 Arylethynyl derivatives HOFFMANN-LAROCHE INC. (US) 2013-08-20 US disclosed
US-20130178456-A1 ARYLETHYNYL DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-07-11 US disclosed
US-8420661-B2 Arylethynyl derivatives HOFFMANN-LA ROCHE INC. (US) 2013-04-16 US disclosed
EP-2558457-A1 ARYLETHYNYL DERIVATIVES F. Hoffmann-La Roche AG (CH) 2013-02-20 EP disclosed
WO-2011128279-A1 ARYLETHYNYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 WO disclosed
US-20110251169-A1 Arylethynyl derivatives HOFFMANN-LA ROCHE, INC. 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178456-A1 ARYLETHYNYL DERIVATIVES GRM5, GRM1, GRM3 BIRC5 4430/4885CLK4 3405/4885
US-20140155602-A1 Arlethynyl Derivatives GRM5, GRIK5, GRM1 BIRC5 2628/4885CLK4 3133/4885
US-20130274464-A1 Arylethynyl Derivatives GRM5, GRM1, GRM3 BIRC5 4430/4885CLK4 3405/4885
US-20110251169-A1 Arylethynyl derivatives GRM5, GRM1, GRM3 BIRC5 4430/4885CLK4 3405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.